Cefazolin antibiotic prophylaxis: Determination of cerebrospinal fluid concentration
Study summary
The objective is to determine the concentration of cefazolin in the cerebrospinal fluid after a recommended antiobiotic prophylaxis by 2g of cefazolin. Our main hypothesis is that the concentration is insufficient to protect the valve from infections.
The secondary objective is to compare our results to known pharmacokinetic models of cefazolin diffusion in the literature. If differences are found we would like to search clinical features that could explain it.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Age \>18 years and programmed for a ventricular shunt surgery at the Hautepierre university hospital in Strasbourg.
Exclusion Criteria:
* Age \<18 years old
* Pregnant women
* Infected patients
* Known cefazolin allergy
* Other molecule used for the antibiotic prophylaxis
* Guardianship or conservatorship
* Patients under curative antibiotherapy
* Non sterile pre operative CSF
* Refusal to participate
Primary outcome measure(s)
Cefazolin concentration in the cerebrospinal fluid — The measure is made when the dura mater is opened just before the valve implantation. Cefazolin concentration in the cerebrospinal fluid.
Trial sites (1)
Facility
City
Region
Status
Hôpitaux Universitaires de Strasbourg
Strasbourg
France
Recruiting
More University Hospital, Strasbourg, France trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
